| Cancer statistics, 2016 | Ca-A Cancer Journal for Clinicians | 2016 | 13.1K |
| Cancer statistics in China, 2015 | Ca-A Cancer Journal for Clinicians | 2016 | 11.3K |
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Blood | 2016 | 5K |
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Blood | 2016 | 4.1K |
| Cancer treatment and survivorship statistics, 2016 | Ca-A Cancer Journal for Clinicians | 2016 | 3.3K |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 1.7K |
| Breast cancer statistics, 2015: Convergence of incidence rates between black and white women | Ca-A Cancer Journal for Clinicians | 2016 | 813 |
| Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 796 |
| Toxicities of chimeric antigen receptor T cells: recognition and management | Blood | 2016 | 727 |
| Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages | Blood | 2016 | 675 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 590 |
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper | Annals of Oncology | 2016 | 548 |
| 'Acute myeloid leukemia: a comprehensive review and 2016 update' | Blood Cancer Journal | 2016 | 542 |
| Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities | Ca-A Cancer Journal for Clinicians | 2016 | 507 |
| 2016 US lymphoid malignancy statistics by World Health Organization subtypes | Ca-A Cancer Journal for Clinicians | 2016 | 504 |
| Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma | Blood | 2016 | 499 |
| ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 497 |
| Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Leukemia | 2016 | 497 |
| Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 488 |
| T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma | Blood | 2016 | 480 |
| The epidemiology of venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 | 477 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group | Blood | 2016 | 463 |
| Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo | Leukemia | 2016 | 455 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Blood | 2016 | 442 |
| Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy | Blood | 2016 | 436 |
